Streetbeat News

Products Services

FEMY

Femasys has announced the achievement of first-patient-in for its pivotal trial of FemBloc, a non-surgical, non-implant, in-office solution for permanent birth control for women.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 12:32 pm

LIXT

LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) has announced a Phase 1b collaborative clinical trial to assess the effectiveness of adding Lixte's LB-100 to GSK's dostarlimab in the treatment of ovarian clear cell carcinoma. The trial is sponsored by The University of Texas - MD Anderson Cancer Center and will also be open at Northwestern University's Robert H. Lurie Comprehensive Cancer Center. LIXTE will provide LB-100; GSK will provide dostarlimab and financial support for the clinical trial.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 12:31 pm

TARA

Protara Therapeutics has announced the dosing of the first patient in its Phase 1b/2 ADVANCED-2 trial of TARA-002 in patients with high grade carcinoma in situ. This marks a significant step in the development of the drug.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 12:31 pm

RLMD

Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced positive efficacy and safety results from the Phase 3 long-term study of REL-1017 in patients with Major Depressive Disorder (MDD). The study showed that patients treated with REL-1017 experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment. The drug was well-tolerated with low rates of adverse events and discontinuations due to adverse events. No new safety signals were detected.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 12:31 pm

SILO

Silo Pharma, Inc. (NASDAQ:SILO) has announced positive pre-clinical data for SPC-15, a targeted intranasal prophylactic for the treatment and prevention of anxiety, PTSD, and other stress-related disorders. The company is working with Kymanox to prepare a pre-Investigational New Drug (IND) package and meeting request with the FDA, with submission targeted for Q1 2024. Kymanox will provide regulatory affairs support, including the development of a clinical pharmacology and biopharmaceutics strategy and program.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 12:29 pm

EVAX

Evaxion Biotech A/S (NASDAQ:EVAX) has announced a partnership with Afrigen Biologics to develop a novel mRNA vaccine against gonorrhea. The vaccine is based on a candidate identified by Evaxion's EDEN™ platform. The collaboration will also utilize mRNA technology from the WHO and Medicines Patent Pool's mRNA Vaccine Technology Transfer Hub. Afrigen will be responsible for the development and commercialization of the vaccine in LMICs and African territories.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 12:26 pm

AVGR

BRDS

ELUT

EXAI

FRTX

SPRY

Shares of several companies including TransCode Therapeutics, Fresh Tracks Therapeutics, EBET, Exscientia, Histogen, Rail Vision, Avinger, Inhibikase Therapeutics, Microbot Medical, and Cheche Group are trading higher in pre-market. Fresh Tracks Therapeutics and Histogen announced plans of liquidation and dissolution. Exscientia and Merck announced collaboration on AI-driven drug discovery. Avinger announced the commercial launch of its Tigereye ST image-guided CTO crossing device. On the other hand, shares of ARS Pharmaceuticals, Connexa Sports Technologies, Bird Global, TD Holdings, AgileThought, Elutia, Digital Transformation Opportunities Corp., Cybin, and Revance Therapeutics are trading lower. ARS Pharmaceuticals received a Complete Response Letter from the FDA for its neffy® Epinephrine nasal spray. Bird Global announced its purchase of micromobility operator Skinny Labs for $19 million. Elutia announced a $26 million private placement of shares.

Portfolio Pulse from Lisa Levin

September 20, 2023 | 12:19 pm

ABT

Abbott Laboratories (ABT) and mAbxience have announced a partnership to commercialize several biosimilars focusing on oncology, women's health, and respiratory diseases in emerging markets in Latin America, Southeast Asia, Middle East, and Africa. The first molecules are expected to launch in 2025.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 12:19 pm

BLNK

Blink Charging has become a provider of electric vehicle charging solutions for Royal Farms. The company will install 30 Blink DC Fast Chargers at Royal Farms locations throughout Maryland and Delaware.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 12:18 pm

KULR

KULR Technology Group will supply Velos Rotors with its VIBE service, a vibration reduction technology. This technology will help reduce noise and vibration while enhancing the overall balance of Velos' V3 UAV helicopter for highly sensitive payloads.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 12:16 pm